Melanoma Institute part of $14m melanoma project grant
25 March 2015
Federal Minister for Health, the Hon. Sussan Ley, announced more than $14 million in funding for a research program to study the molecular determinants of risk, progression and treatment response in melanoma.
The research, funded as part of the National Health and Medical Research Council (NHMRC) Program scheme, will commence in 2016 and will be administered through Macquarie University in Sydney. The team’s investigators are largely based at the University of Sydney, as well as the Centenary Institute, the Westmead Millennium Institute for Medical Research, and the QIMR Berghofer Medical Research Institute.
All investigators are part of MIA, the world’s largest cancer centre dedicated to research and treatment of melanoma, and have been linked as a NHMRC Program since 2006. Treating 1900 new melanoma patients annually, the MIA’s repository of clinical research data and melanoma biospecimens is the largest in the world.
Lead researcher Professor Rick Kefford from MIA and Macquarie University said the project had real prospects of accelerating prevention and early detection of melanoma.
“In this era of rapid change the program could make realistic progress towards a cure of metastatic disease,” Professor Kefford said.
MIA tumour samples and data from people receiving targeted and immune treatments for melanoma are driving these promising advances. The Program has also recruited thousands of people from the community, and families with a strong history of melanoma, to lead discovery of melanoma risk genes.
“In the last few years our program has helped drive large-scale genomic analysis of melanoma, and this will continue to be a cornerstone of our research,” says Professor Graham Mann of MIA, Westmead Millennium Institute and the University of Sydney. “These approaches have already been highly successful, and we have great hopes for better prevention, detection and treatment of melanoma in the future,” he said.
The World Health Organisation (WHO) is releasing the 4th edition of Classification of Skin Tumours.
Former Executive Director of Melanoma Institute Australia Professor John Thompson awarded the prestigious 2018 RPA Foundation Research Medal.
Clinicians, patients and other stakeholders in the cancer community are invited to make submissions in support of the PBS listing for pembrolizumab.
The World Congress on Cancers of the Skin 2018 has featured many minds from MIA sharing their expertise and wealth of knowledge with over 1000 attendees from around the world.
Melanoma Institute Australia is delighted to announce the appointment of Matthew Browne as Chief Executive Officer (CEO).
It was a full house this week at Melanoma Institute Australia thanks to our ‘Melanoma in Practice: Nurse Conference’.
A new study from The University of Sydney shows that sunscreen reduces melanoma risk by 40 per cent when used from a young age.
Melanoma Institute Australia (MIA) has launched a free e-learning portal to educate healthcare professionals about the latest advances in melanoma diagnosis and treatment.
When David lost his life last year, he was 33, with three daughters under six.
Clinical trials are just that – trials in a clinical setting to evaluate the effectiveness or otherwise of individual and combination treatments.
Melanoma Institute Australia scooped the award pool at the Annual Scientific Meeting of the International Academy of Pathology.
Melanoma patients across Australia will benefit from the release of updated clinical care guidelines.
An American study has discovered a link between early detection and marital status in melanoma diagnosis.
An international course on melanoma pathology in Paris, France co-directed by Professor Richard Scolyer took place over the weekend.
Professor Richard Scolyer highlights the difficulties of diagnosis following the Australian Story feature program on Emma Betts.
Cancer Australia releases 'stage at diagnosis' data for top five incidence cancers – including melanoma
For the first time in Australia, national data has been released on cancer stage at diagnosis. This data explores the top five incidence cancers – female breast cancer, colorectal, lung, prostate cancers and melanoma.
'Dear Emma' - a tribute to the life and times of a young woman determined to raise awareness about melanoma.
Carole Renouf, CEO for MIA thanks Toyota for helping fuel ongoing melanoma research.
Fraser Dykes tackled the Kokoda Trail on an eight day trek in memory of his friend Mark 'Bod' Boddison.